
Chronic Kidney Disease (CKD) Clinical Guidelines and Research Trials
Bayer is an innovation leader in the area of cardiovascular diseases, with a long-standing commitment to delivering science for a better life by advancing a portfolio of innovative treatments. The heart and the kidneys are closely linked in health and disease, and Bayer is working in a wide range of therapeutic areas on new treatment approaches for cardiovascular and kidney diseases with high unmet medical needs. The cardiology franchise at Bayer already includes a number of products and several other compounds in various stages of preclinical and clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cardiovascular diseases are treated.
Chronic kidney disease (CKD) is a frequent complication of type 2 diabetes (T2D) that affects approximately 40% of patients. T2D disproportionately affects Black and Hispanic Americans. Despite its frequency, most patients are unaware of CKD and the increased risk of cardiovascular events associated with it. Early detection of CKD may improve patient outcomes and help prevent cardiovascular-related events and deaths. Diabetes is estimated to affect over 10% of adults in the U.S., primarily those over the age of 45, with type 2 diabetes (T2D) accounting for 90-95% of cases. In patients with T2D, up to 40% develop chronic kidney disease (CKD), which damages the kidney and reduces its ability to filter waste. CKD also greatly increases the risk of cardiovascular complications, with the risk of cardiovascular death increasing as CKD progresses. In fact, patients with stage 3 CKD are over 10 times more likely to die than progress to kidney failure. Damage from CKD cannot be reversed, but with the advent of new kidney-protecting treatments, early detection of CKD allows patients and their health care providers to create a plan that may slow CKD progression and reduce cardiovascular risk.
Unfortunately, fewer than a quarter of at-risk patients are tested for CKD. Because many patients are unaware of the disease risk—9 out of 10 patients with CKD do not know they have it—they may not ask their doctors to be screened. Without screening, CKD often progresses unnoticed because symptoms do not appear until severe kidney damage occurs and a patient has an imminent need for treatment.
NCQA- Bayer Kidney Health Toolkit
National Kidney Foundation – Ongoing Kidney Disease Trials
In addition to its work with PHA, Bayer works with other leading medical and clinical organizations on offering resources and sharing research on one of its major priorities — Chronic Kidney Disease (CKD) to improve the quality of care of this common, but under-recognized condition. Fifteen percent (15%) of US adults are estimated to have chronic kidney disease — about 37 million people. Please click on the following, to learn more:
Bayer – Cardiovascular and Kidney Diseases Resources
Centers for Disease Control and Prevention (CDC)
NCQA Kidney Health Toolkit The National Committee for Quality Assurance (NCQA) toolkit was developed with financial support from Bayer Healthcare Pharmaceuticals, Inc.
National Kidney Foundation (NFK) Bayer, along with NKF and award-winning actress, Debbie Allen launched the “Are You the 33%?” a national public awareness campaign in February 2021 to focus attention on the increased risk of developing chronic kidney disease.
American Society of Nephrology ASN leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care. Bayer is a platinum partner.
American Nephrology Nurses Association
American Association of Kidney Patients
Living with Chronic Kidney Disease can be extremely challenging and stressful for both patients and for those who care for them. In efforts to empower CKD patients and their caregivers to be more knowledgeable as to this condition and be more proactive in their care and treatment, Bayer and PHA are pleased to share the following resources. Please know that you are not alone. There is a range of support available to help you assume control, keep informed and take action:
Bayer’s Managing Chronic Kidney Disease Learn about the stages of chronic kidney disease (CKD), steps you can take to slow CKD progression, and an introduction to kidney dialysis and transplant.
Family and Caregiver Support from the National Kidney Foundation
Renal Support Network
American Association of Kidney Patients Educational Resources
